In its order, CJ Upadhyaya-led bench directed PIL litigant to submit to CDSCO the scientific studies and data relied upon in ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Ecnoglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist analogue, similar to the blockbuster obesity drug semaglutide. These drugs mimic the hormone GLP-1, which is involved in regulating ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

UK health authorities are investigating pancreatitis cases linked to weight-loss drugs like Ozempic and Mounjaro. We spoke to doctors for clarity on risks, side effects, and the role of genetics.

The UK's health regulator is investigating Ozempic and Mounjaro after linking the drugs to hundreds of severe illnesses and ...

Projections for the near future indicate that the glucagon-like peptide GLP-1 agonists weight loss drugs market size will continue to surge, reaching $28.91 billion in 2029 at a CAGR of 16.6%.

Liraglutide, a member of the family of blockbuster weight-loss drugs, reduces headaches by half in a small study.

Glucagon-Like-Peptide-1 Agonists, like Ozempic, have become extremely popular for weight loss. Here are some of the side ...